Beximco Pharmaceuticals Ltd.

Beximco Pharmaceuticals Ltd. is a Bangladesh-based pharmaceutical manufacturer and exporter headquartered at 19 Dhanmondi R/A, Road No. 7, Dhaka 1205. Established in 1980, the company manufactures medicines under an allopathic licence and operates registered manufacturing sites in Kaliakoir and Tongi, Gazipur.

What they manufacture

The company manufactures generic medicines and active pharmaceutical ingredients (APIs). It began manufacturing products under licensing arrangements in 1980 and launched its own formulation brands in 1983, building its operations around the production of medicines intended to provide access to quality and affordable treatment.

Company development and global operations

Beximco Pharma has expanded from its early manufacturing activities into international pharmaceutical operations, with medicines exported to more than 50 countries, including regulated markets in the USA, Europe, Canada and Australia. Its manufacturing facilities have been accredited by regulatory authorities in the USA, Europe, Australia, Canada, Latin America and South Africa.

The company has also expanded through acquisitions. In 2018, it acquired a majority stake in Nuvista Pharma, formerly Organon Bangladesh. In 2021, it acquired a 54.6% majority stake in Sanofi Bangladesh Limited, which was renamed Synovia Pharma PLC in 2022. The company employs more than 4,700 people across pharmaceutical, scientific, engineering, commercial and other professional roles.

Registration and licensing

• DGDA status: Functional
• Licence category: Allopathic
• DGDA registered addresses: Kaliakoir, Gazipur; Tongi I/A, Gazipur

An allopathic licence covers the manufacture of conventional modern medicines regulated through Bangladesh's drug regulatory system. A Functional DGDA status indicates that the registered manufacturing operation is recorded as functional; this is distinct from statuses such as suspended or non-functional.